Amlodipine Besylate And Olmesartan Medoxomil Tablet, Film Coated
Product Images NDC 51407-859

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Amlodipine Besylate And Olmesartan Medoxomil (NDC 51407-859). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Amlodipine Besylate (51407-857-30 test.jpg)

Label for Amlodipine and Olmesartan Medoxomil Tablets 5 mg/20 mg, film-coated tablets, oral use, in a 30-tablet package. The label includes NDC 51407-857-30 and states each tablet contains 13.9 mg of amlodipine besylate. Marketed by GSMS, Incorporated, Camarillo, CA.*

FDA Label Image

Figure 1: Probability Of Achieving Systolic Blood Pressure (sbp) < 140 Mmhg At Week 8 With Locf (Azor 01)

A line graph showing the percentage of subjects with systolic blood pressure (SBP) ≥140 mmHg plotted against baseline SBP (mmHg). Four groups are represented: Placebo, AML 10 mg, OM 40 mg, and Azor 10/40. The graph illustrates trends of decreasing percentages across increasing baseline SBP for each treatment group.*

FDA Label Image

Figure 2: Probability Of Achieving Diastolic Blood Pressure (dbp) < 90 Mmhg At Week 8 With Locf (Azor 02)

A line graph showing the percentage of diastolic blood pressure (DBP) under 90 mmHg plotted against baseline DBP in mmHg. Four data series are labeled: Placebo, AMIL 10 mg, OM 40 mg, and Azor 10/40 mg, demonstrating their comparative effects on controlling DBP.*

FDA Label Image

Figure 3: Probability Of Achieving Systolic Blood Pressure (sbp) < 130 Mmhg At Week 8 With Locf (Azor 03)

A line graph showing the percentage of subjects with systolic blood pressure (SBP) less than 130 mmHg against baseline SBP in mmHg. Four treatment groups are represented: Placebo, AML 10 mg, OM 40 mg, and Azor 10/40 mg, with Azor 10/40 mg maintaining the highest percentage of subjects below 130 mmHg across baseline SBP values.*

FDA Label Image

Figure 4: Probability Of Achieving Diastolic Blood Pressure (dbp) < 80 Mmhg At Week 8 With Locf (Azor 04)

A line graph depicting the proportion of patients with diastolic blood pressure (DBP) less than 80 mmHg across different baseline DBP values ranging from 95 to 110 mmHg. The graph compares responses among groups receiving placebo, 10 mg amlodipine (AML), 40 mg olmesartan medoxomil (OM), and a combination of 10/40 mg (presumably amlodipine/olmesartan), indicated by separate lines with different markers.*

FDA Label Image

The Structural Formula For Amlodipine Besylate Is Chemically Described As 3-ethyl-5-methyl (±)-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate, Monobenzene (Azor 05)

Chemical structure of amlodipine besylate and olmesartan medoxomil indicating molecular components and arrangement, including the besylate moiety shown as part of the structure.*

FDA Label Image

The Structural Formula For Olmesartan Medoxomil Is Chemically Described As 2,3-dihydroxy-2-butenyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[p-(o-1h-tetrazol-5-ylphenyl)benzyl]imidazole-5-carboxylate, C (Azor 06)

Chemical structure diagram representing the active ingredients amlodipine besylate and olmesartan medoxomil. The structural formula shows molecular bonds and constituent atoms of the compounds.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.